|
市場調查報告書
癌症疫苗研發的最新狀況
Cancer Vaccines Fantasy or Future?
|
本報告已在2011年07月19日停止出版。
迄今進行了許多利用免疫系統的多樣性癌症治療，但是卻沒有開發出任何一項突破性的治療法。現階段最成功的可以說是抗體及細胞激素療法等的「被動式」免疫療法。由於 醫藥界對人體癌症的分子特性及癌症免疫學的理解逐漸加深，並且發現腫瘤相關抗原（TAA），因此以 TAA 為基礎的疫苗研發正持續開發中。但是一般認為所謂的癌症疫苗還 是停留在手術後殘留腫瘤的去除及延緩癌症擴散的使用上，藉以達到延長壽命的作用。
近來在醫藥及生物技術領域的調查分析上富有績效的瑞典調查公司 BioSeeker Group ，調查與分析癌症疫苗的最新研發狀況，並有系統地出版綜合報告書 "Cancer Vaccines Fantasy or Future?" 。
此報告書在下面的內容裡，除了說明癌症免疫療法的相關分析；也探討各種癌症替代疫苗的最新開發狀況 ，及相關主要企業檔案等。本商品由於是事前預定的緣故，價格、內容及出版時間可能會有更改的情況發生。詳細內容敬請來電詢問。
1. 調查方法
2. 癌症免疫療法的概要
3. 改良式策略
4. 癌症替代疫苗的進展分析
- Actimmune
- Allovectin-7
- Avicine
- BEC2
- Canvaxin
- CeaVac
- CaPVax. (DCVax)
- Gastrimmune
- GMK
- LymphoCide
- Melacine
- M-Vax
- MyVax
- Oncophage
- OncoVAX
- Osidem
- Ovarex
- Provenge
- Theratope
- TroVax
5. 企業檔案
附錄：替代治療藥的發展檔案
Executive Summary
The concept of utilizing the immune system for the treatment of cancer has been tried for some time without any direct breakthrough success. So far "passive" immunotherapy has experienced most success, with antibody and cytokine therapy leading the way.
An example of difficulties and risks associated with this field is shown by Dendreons latest failure, in January 2005 of their late stage cancer vaccine candidate Provenge. The new and updated progress analysis report "Cancer Vaccines Fantasy or Future" by BioSeeker Group continues to provide the latest information and analysis on industry related as well as important academic activities.
Active immunotherapy strategies have emerged and progress in the molecular characterization of human tumors and a better understanding of tumor immunology has resulted in the discovery of tumor-associated antigens (TAAs). TAA-based vaccines are at present being evaluated. It is broadly admitted that therapeutic vaccines will initially and in the near future be efficient only on a limited tumor burden. Cancer vaccines ought to be used in an adjuvant setting, for instance in order to remove residual disease after surgical treatment of the tumor. As well, in light of the fact that some of these experimental vaccines can elicit immune and clinical responses even in patients with advanced cancer, cancer vaccines can also be considered for slowing down disease progression and conserve quality of life.
BioSeeker Group has since several years continuously studied the progress in cancer immunotherapy strategies. In this newly updated progress analysis we not only provide a solid background and information structure, we also bring the latest within cancer vaccine achievements.
Reasons Why You Should Read This Report:
- Get a solid background of what is happening in the Cancer Vaccine field.
- Learn how the strategies have improved.
- Make sure that you have the latest information about the most prominent Cancer Vaccine candidates.
- Speed up your R&D by finding collaborators or partners.
Table of Contents
BioSeeker Group methodology
Introduction to cancer immunotherapy
Improved strategies
Progress analysis on cancer vaccine candidates:
- Allovectin-7
- Avicine
- BEC2
- Canvaxin
- CeaVac
- CaPVax. (DCVax).
- Gastrimmune
- GMK
- LymphoCide
- Melacine
- M-Vax
- MyVax
- Oncophage
- OncoVAX
- Osidem
- Ovarex
- Provenge
- Theratope
- TroVax
Company Profiles
Appendix: Progress profiles on therapeutic candidates
|
